Matthew Metzger | Alliance and Business Manager
Oxford BioTherapeutics Ltd
Matthew joined Oxford Biotherapeutics in 2022 as a program manager. He is dedicated primarily to external innovation, coordinating and delivering target validation data for partnership programs, and business development, developing content and strategies for current and future partnerships. He currently oversees the ADC and TCE development pipeline of over 10 partnered programs across multiple collaborations. After completing grad school at UC Berkeley, he has spent years of experience helping early-stage biotech startups scale. He is passionate about maximizing the quantity and quality of science produced every day.
Appearances:
Festival of Biologics Day 2 @ 14:50
OGAP®-Verify: An Enhanced Target Discovery Platform for First In Class ADC and TCE Target Discovery
My discussion will focus on how we at Oxford BioTherapeutics (OBT) leverage our word class OGAP-Verify target discovery database to identify novel targets which are significantly de-risked prior to significant investment. OGAP-Verify includes data on every membrane protein, including expression in cancer and normal tissues. Additionally, we can predict clinical efficacy and toxicities as well as antigen density on tissues and cell lines. Finally, I will provide insight in how OBT can identify the next-generation of ADC targets to reach patients who still have no access to targeted treatments.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events